Breakthroughs in Immunotherapy and Checkpoint Inhibitors
Immunotherapy has become the cornerstone of treatment for advanced or recurrent endometrial cancer in 2026.
Drugs such as pembrolizumab, dostarlimab, and durvalumab are now used as frontline therapies in combination with standard chemotherapy (carboplatin and paclitaxel). These agents work by blocking the PD-1/PD-L1 pathway, which essentially "unmasks" the cancer cells, allowing the patient's own immune system to recognize and destroy them. This approach is particularly effective for the 30% of patients whose tumors are mismatch repair deficient (dMMR), leading to long-term remission in cases that were previously considered untreatable.
1 vista
